Evaluating Response Rates With CC-92480 Combination in Multiple Myeloma

July 07, 2020

Paul G. Richardson, MD, discusses the response rates observed in the first-in-human phase 1 trial of CC-92480 and dexamethasone in patients with relapsed/refractory multiple myeloma.

Expanding Options for Relapsed/Refractory HER2+ Metastatic Breast Cancer

July 07, 2020

Dr Mark Pegram and Dr Julie Gralow discuss treatment options in relapsed/refractory HER2+ metastatic breast cancer.

Toxicity Profile of CAR T-Cell Therapy Appears Safe in Follicular and Marginal Zone Lymphomas

July 06, 2020

Caron Jacobson, MD, discusses the safety findings from the phase 2 ZUMA-5 tidal evaluating axicabtagene ciloleucel in patients with follicular lymphoma and marginal zone lymphoma.

Long-Term Results of Ibrutinib/Umbralisib Show Efficacy in CLL and MCL

July 06, 2020

Matthew S. Davids, MD, discusses the long-term follow-up of a phase 1/1b trial for patients with relapsed/refractory chronic lymphocytic leukemia or mantle cell lymphoma receiving ibrutinib and umbralisib.

VISION Trial Produces Positive Data in NSCLC With MET Exon 14 Mutations

July 03, 2020

Xiuning Le, MD, PhD, discusses the results of tepotinib in patients with advanced non-small cell lung cancer and a MET exon 14 skipping mutation.

Investigating Combinations in Recurrent or Metastatic Cervical Cancer

July 02, 2020

Bradley Monk, MD, discusses the phase 1b/2 innovaTV 205 trial in patients with recurrent or metastatic cervical cancer.

HER2CLIMB Study Shows Efficacy in HER2 Breast Cancer With Brain Metastases

July 01, 2020

Nancy U. Lin, MD, discusses the latest findings from the HER2CLIMB study of either tucatinib or placebo, added to trastuzumab and capecitabine, for patients with previously treated HER2-positive metastatic breast cancer who have brain metastases.

Expanding Options for Relapsed/Refractory Gastrointestinal Stromal Tumors

July 01, 2020

Key opinion leaders discuss the evolving treatment paradigm for relapsed/refractory gastrointestinal stromal tumors, and provide an overview of supplemental data presented at the ASCO (American Society of Clinical Oncology) 2020 Annual Meeting.

Analyzing the ESPAC-5F Trial in Borderline Resectable Pancreatic Cancer

June 30, 2020

Shubham Pant, MD, discusses the ESPAC-5F trial methods and efficacy in patients with pancreatic cancer.

Graft-Versus-Host Disease

June 30, 2020

Experts in stem cell transplantation review the background of graft-versus-host disease and discuss 3 clinical cases and individualized treatment approaches.